Keyword: Bydureon

Novo Nordisk has secured 2018 formulary coverage for Ozempic from leading U.S. pharmacy benefit manager Express Scripts.

AstraZeneca is hoping a new formulation of Bydureon will give the med some competitive firepower against a field of tough rivals.

Anyone looking for a heart-helping class effect from GLP-1 diabetes meds wouldn't be encouraged by the Bydureon data AstraZeneca rolled out Thursday.

Pay-for-performance deals have been gaining popularity among drugmakers, and Harvard Pilgrim has been ready and willing to strike up partnerships. The latest to do so? AstraZeneca.

AstraZeneca finally has cardiovascular outcomes data for one of its top diabetes contenders. But the new results don’t measure up to rivals' studies.

AstraZeneca has licensed diabetes drugs Byetta and Bydureon to 3SBio to kickstart sales growth in China.

When it comes to controlling blood sugar in Type 2 diabetes patients, two drug classes may be better than one, AstraZeneca said Friday.

Sanofi finally won FDA approval of its long-awaited GLP-1 diabetes drug Adlyxin. But “finally” is the operative word, and the med will have to scramble with new and formidable rivals to win market share.

AstraZeneca now has a one-stop shop for patients. It's a new all-in-one pharma app that offers savings card access, refill reminders and customer care contacts for the company's top brands.